Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

305
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
305
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

263
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
263
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

262
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
262
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

265
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
265
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

421
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
421
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

342
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
342

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The effect of diketopyrrolopyrrole (DPP) group inclusion in p-cyanophenyl end-capped oligothiophene used as a dopant in P3HT:PCBM BHJ solar cells.

Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology·2014
Same author

[Penile cancer: flow cytometry study of ploidies in 90 patients].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2000
Same author

[Cancer of the urethra in women: experience of the National Institute of Cancer of Brazil: 1992-1997].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·1999
Same author

Auditory perception in early lateralized brain damage.

Cortex; a journal devoted to the study of the nervous system and behavior·1984

Related Experiment Video

Updated: Sep 14, 2025

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

26.0K

SGLT2 INHIBITORS: FROM GLYCEMIC CONTROL TO CARDIO-RENAL PROTECTION

Kh Evloev1, D Snitsa2, D Pankov2

  • 11North-Western State Medical University named after I.I. Mechnikov, Saint-Petersburg, Russia.

Georgian Medical News
|July 22, 2025
PubMed
Summary

Sodium-glucose cotransporter 2 (SGLT2) inhibitors offer significant cardiorenal protection beyond diabetes management. Clinical trials reveal mechanisms like hemodynamic modulation and anti-inflammatory effects, establishing SGLT2 inhibitors as key for heart and kidney health.

More Related Videos

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.0K
Assessment of Kidney Function in Mouse Models of Glomerular Disease
09:16

Assessment of Kidney Function in Mouse Models of Glomerular Disease

Published on: June 30, 2018

17.9K

Related Experiment Videos

Last Updated: Sep 14, 2025

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

26.0K
Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.0K
Assessment of Kidney Function in Mouse Models of Glomerular Disease
09:16

Assessment of Kidney Function in Mouse Models of Glomerular Disease

Published on: June 30, 2018

17.9K

Area of Science:

  • Cardiology
  • Nephrology
  • Endocrinology
  • Pharmacology

Background:

  • Sodium-glucose cotransporter 2 (SGLT2) inhibitors were initially developed for type 2 diabetes mellitus (T2DM).
  • Emerging evidence highlights their substantial cardioprotective and nephroprotective benefits independent of glycemic control.
  • These effects necessitate a comprehensive review of their mechanisms and clinical applications.

Purpose of the Study:

  • To review the mechanisms underlying the cardioprotective and nephroprotective effects of SGLT2 inhibitors.
  • To summarize clinical implications across diverse patient populations, including those with and without diabetes.
  • To assess the role of SGLT2 inhibitors in heart failure and chronic kidney disease.

Main Methods:

  • Review of landmark cardiovascular and renal outcome trials.
  • Evaluation of physiological and molecular mechanisms (hemodynamic modulation, anti-inflammatory/antifibrotic effects, energetics).
  • Assessment of SGLT2 inhibitor efficacy in heart failure (HFrEF/HFpEF) and chronic kidney disease (CKD).

Main Results:

  • SGLT2 inhibitors demonstrate significant benefits in cardiovascular and renal outcomes.
  • Mechanisms include improved myocardial and renal energetics, reduced inflammation, and antifibrotic actions.
  • Efficacy is shown in heart failure and CKD, irrespective of diabetic status.

Conclusions:

  • SGLT2 inhibitors provide substantial cardiorenal protection beyond glucose lowering.
  • Their multifaceted mechanisms support their use in managing heart failure and CKD.
  • Clinical guidelines now recognize SGLT2 inhibitors as essential for cardiorenal protection.